Hi Hankmanhub, I remember your post and thank you for reposting it with the consideration of poly-ICLC in the mix. I'm sure your ideas helped me in my thought process. I personally don't know how poly-ICLC needs to be treated. Does it need a RA approval with or without DCVax? Can we count on it to be there when we need it for future trials? Do other trials and compassionate care cases support the original very small Ph I trial that shows so much efficacy when combined with DCVax? How well is the Ph II trial going? So many questions that we don't have the answers to. I don't think Dr. Liau would be including the Ph I trial with poly-ICLC in her presentations if she didn't think this adjuvant was important for improving efficacy in brain cancer. I think she knows a whole lot more than we do! There's a reason why poly-ICLC seems to be incorporated in the word, DCVax, on her presentation pages, as others have pointed out. There's a reason why Dr. Liau continues to use it in conjunction with DCVax, as if they were one and the same. Therefore, I think NWBO needs to hammer out some kind of an agreement with Oncovir, Inc., and perhaps already has. Whether that's a contract, a partnership, or a merger, I don't know. But I think we'll know soon what management has decided.
Market Data 
Markets 
AI
